Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | TACR2 | P21452 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | GYPA | P02724 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8960128 | 0.80 | SLC6A2 (0.52) | SLC6A2TACR2PDE4DLGALS8TSHR | |
| SCHEMBL8960215 | 0.80 | SLC6A2 (0.52) | SLC6A2TACR2PDE4DLGALS8TSHR | |
| SCHEMBL8960222 | 0.80 | SLC6A2 (0.52) | SLC6A2TACR2PDE4DLGALS8TSHR | |
| SCHEMBL8960525 | 0.80 | SLC6A2 (0.52) | SLC6A2TACR2PDE4DLGALS8TSHR | |
| SCHEMBL8960350 | 0.80 | SLC6A2 (0.52) | SLC6A2TACR2PDE4DLGALS8TSHR | |
| SCHEMBL8960125 | 0.80 | SLC6A2 (0.52) | SLC6A2TACR2PDE4DLGALS8TSHR | |
| SCHEMBL31124807 | 0.80 | SLC6A2 (0.46) | SLC6A2TACR2PDE4DLGALS8TSHR | |
| SCHEMBL6659183 | 0.78 | SLC6A2 (0.51) | SLC6A2TACR2PDE4DLGALS8TSHR | |
| SCHEMBL630301 | 0.78 | SLC6A2 (0.51) | SLC6A2TACR2PDE4DLGALS8TSHR | |
| SCHEMBL969974 | 0.78 | SLC6A2 (0.51) | SLC6A2TACR2PDE4DLGALS8TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269285-A1 | Novel Compounds of the Family of Iminosugars, Uses Thereof for Trewating Lysosomal Diseases, and Method for Preparing Same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269285-A1 | Novel Compounds of the Family of Iminosugars, Uses Thereof for Trewating Lysosomal Diseases, and Method for Preparing Same | GBA1, GAA, MAN2B1 | SLC6A2 2390/4885TACR2 3978/4885PDE4D 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.